Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Nazla-i-muzmin (Chronic rhinosinusitis) is one of the commonest diseases prevalent all around the world. In India one in eight Indian suffers from this ailment. The current medical management and surgical intervention do not provide complete cure as a result there is a need to search a better alternative drug. The main objective of this study was to evaluate the safety and efficacy of a Unani formulation in the management of chronic rhinosinusitis. This study was designed as a randomised, controlled, parallel group and open label clinical study. It was carried out in 60 participants (30 participants in each group) of chronic rhinosinusitis aged between 18-65 years of either sex. The participants were enrolled based on the symptoms rhinorrhoea, sneezing, facial pain, nasal blockage, post nasal drip and thick nasal discharge. The participants of the test group was treated with a Unani formulation (9 gm) whereas Levocetrizine (10mg) was given to the participants of the control group once at night. In this study the average age of the participants was 30.36 (±10.20) years and 32.63 (±10.97) years in the control and test groups respectively with an average chronicity of 31.26 (± 43.46) months in the control group and 23.86 ± 39.4 months in the test group. The Unani formulation was found effective in reducing rhinorrhoea, sneezing, facial pain, nasal obstruction, post nasal discharge and thick nasal discharge. The snot score at post treatment comparing to the baseline was reduced to 2.1 and 2.0 in the test and control groups respectively. The Unani formulation improved the symptoms of chronic rhinosinusitis in the test group due to the possible action of the ingredients having, deobstruent, anti-inflammatory, concoctive, analgesic, expectorants and antimicrobial activities. It was concluded that the outcome of the study showed the successful management of chronic rhino-sinusitis. The formulation was well tolerated and showed no adverse effect.
Abstract
Nazla-i-muzmin (Chronic rhinosinusitis) is one of the commonest diseases prevalent all around the world. In India one in eight Indian suffers from this ailment. The current medical management and surgical intervention do not provide complete cure as a result there is a need to search a better alternative drug. The main objective of this study was to evaluate the safety and efficacy of a Unani formulation in the management of chronic rhinosinusitis. This study was designed as a randomised, controlled, parallel group and open label clinical study. It was carried out in 60 participants (30 participants in each group) of chronic rhinosinusitis aged between 18-65 years of either sex. The participants were enrolled based on the symptoms rhinorrhoea, sneezing, facial pain, nasal blockage, post nasal drip and thick nasal discharge. The participants of the test group was treated with a Unani formulation (9 gm) whereas Levocetrizine (10mg) was given to the participants of the control group once at night. In this study the average age of the participants was 30.36 (±10.20) years and 32.63 (±10.97) years in the control and test groups respectively with an average chronicity of 31.26 (± 43.46) months in the control group and 23.86 ± 39.4 months in the test group. The Unani formulation was found effective in reducing rhinorrhoea, sneezing, facial pain, nasal obstruction, post nasal discharge and thick nasal discharge. The snot score at post treatment comparing to the baseline was reduced to 2.1 and 2.0 in the test and control groups respectively. The Unani formulation improved the symptoms of chronic rhinosinusitis in the test group due to the possible action of the ingredients having, deobstruent, anti-inflammatory, concoctive, analgesic, expectorants and antimicrobial activities. It was concluded that the outcome of the study showed the successful management of chronic rhino-sinusitis. The formulation was well tolerated and showed no adverse effect.
참고문헌 (25)
- Bita A, "An alternative treatment for Candida infections with Nigella sativa extracts", European Journal of Hospital Pharmacy: Science and Practice, 19, pp.162~ (2012)
- Adams PF, "Current estimates from the national health interview survey, 1994. Vital and health statistics", Series 10, Data from the National Health Survey, 193(1), pp.1~260 (1995)
- "U.S census bureau, International data base" (2004)
- "Ikseer Azam", YNM, 515~
- Anonymous, "Standardization of Single Drug of Unani medicine", pp.196~200 (1992), CCRUM
- "The Unani Pharmacopoeia of India", 1(1), pp.42~43 (2007), Ministry of Health & family Welfare, Dept. of AYUSH
- Benninger SM, "Adult chronic rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysiology", Otolaryngology-Head and Neck Surgery, 129(3), pp.S1~S32 (2003)
- Braunwald E, "Harrison's principles of internal medicine" (2001), McGraw Hill
- Chaturvedi A, "A Cross-Sectional Study on Demographic and Clinical Profile of Chronic Rhinosinusitis (CRS) Patients in a Tertiary Care Hospital", Galore International Journal of Health Sciences and Research, 5(1), pp.17~19 (2020)
- Dar AK, "Demographic Study of Sinusitis in Patients Visiting Govt: Unani Hospital Srinagar and Ayush Centres in Kashmir", Medical Journal of Islamic World Academy of Sciences, 109(893), pp.1~4 (2013)
- Ghulam Nabi Munshi, "Makhzanul Mufradat wa Murakkabat", pp.100~ (2007), CCRUM
- Philip I Hair, "Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies", Drugs, 66(7), pp.973~996 (2006), Springer Science and Business Media LLC[DOI]
- Hakeem M, "Bustanul Mufradat", pp.477~ (2002), Idara Kitabul Shifa
- Hall IS, "Disease of Nose Throat and Ear", pp.61~68 (1981), Longman Group Ltd
- Hodgson TA, "Medical expenditures for major diseases, 1995", Health Care Financing Review, 21(2), pp.119~ (1999)
- Ibn Baitar, "Al-Jamiul Mufradatul Advia. wa al-Aghziya, (Urdu translation CCRUM). III volume", pp.271~275 (1999), Ministry of Health and Family Welfare
- Ibn Baitar, "Al-Jamiul Mufradatul Advia. wa al-Aghziya", pp.248~249 (1999), Ministry of Health and Family Welfare
- Kabīruddīn HM, "Makhzan al-Mufradāt", pp.460~461, Ejaz Publishing House
- Mihail F. Herbal, "traditional and alternative remedies, In Common Cold", pp.309~347 (2009)
- Ozaki Y, "Antiinflammatory effect of mace, aril of Myristica fragrans Houtt. and its active principles", Jpn J Pharmacol, 49(2), pp.155~163 (1989)
- Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, Josephs S, Pung YH. Healthcare expenditures for sinusitis in 1996 : contributions of asthma, rhinitis, and other airway disorders, "Journal of Allergy and Clinical Immunology", 1999;, 103(3), pp.408~414
- Schlossberg D, "Infections of the Head and Neck", pp.81~87 (1987), Springer
- Seys SF, "Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The my Sinusitis Coach project by EUFOREA", Allergy, 75(11), pp.2867~2878 (2020)
- Shamshuddin IQ, "Tibb-i-Nabvi", pp.553~556 (2008), Al Darul Salfia Mumbai
- Tembhurne, SV, "A review on therapeutic potential of Nigella sativa (kalonji)seeds", Journal of Medicinal Plants Research, 8(3), pp.167~177 (2014)